title: Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides.
abstract: Two members of the mammalian Toll-like receptor (TLR) family, TLR2 and TLR4, have been implicated as receptors mediating cellular activation in response to bacterial LPS. Through the use of mAbs raised against human TLR2 and TLR4, we have conducted studies in human cell lines and whole blood to ascertain the relative contribution of these receptors to LPS induced cytokine release. We show that the contribution of TLR2 and TLR4 to LPS-induced cellular activation correlates with the relative expression levels of these two TLRs in a given cell type. In addition, we have found that significant differences in cell stimulatory activity exist between various smooth and rough LPS types that cannot be ascribed to known LPS structural features. These results suggest that impurities in the LPS may be responsible for some of the activity and this would be in agreement with recently published results of others. Upon repurification, none of the commercial LPS preparations activate cells through TLR2, but continue to stimulate cells with comparable activity through TLR4. Our results confirm recent findings that TLR4, but not TLR2, mediates cellular activation in response to LPS derived from both Escherichia coli and Salmonella minnesota. Additionally, we show that TLR4 is the predominant signaling receptor for LPS in human whole blood.
authors.affiliation: Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA.
authors.forename: R I
authors.initials: RI
authors.lastname: Tapping
authors.forename: S
authors.initials: S
authors.lastname: Akashi
authors.forename: K
authors.initials: K
authors.lastname: Miyake
authors.forename: P J
authors.initials: PJ
authors.lastname: Godowski
authors.forename: P S
authors.initials: PS
authors.lastname: Tobias
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D029721:Drosophila Proteins; D004926:Escherichia coli / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D016209:Interleukin-8 / Q000096:biosynthesis; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000302:isolation & purification / Q000378:metabolism* / Q000494:pharmacology; D008562:Membrane Glycoproteins / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D009000:Monocytes / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D011956:Receptors, Cell Surface / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D012475:Salmonella / Q000737:chemistry / Q000276:immunology*; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology*; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors; D014162:Transfection; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D029721:Drosophila Proteins; D016209:Interleukin-8; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; C495342:TLR2 protein, human; C495345:TLR4 protein, human; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors; D014409:Tumor Necrosis Factor-alpha